Ultrasensitive ctDNA Detection via UMI Error Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer patient management techniques face challenges in detecting minimal residual disease (MRD) due to low sensitivity in detecting circulating tumor DNA (ctDNA) amidst a high background of wild-type DNA, particularly at low allele frequencies, which limits early diagnosis and treatment monitoring.
Innovation Solution
A method involving a data processing system that selects target genomic regions with known variants, calculates mutant molecule loads, models background noise, and determines tumor burden and statistical significance using unique molecular identifiers and multinucleotide contexts to enhance detection sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If plasma genotyping assays are used to detect ctDNA, then cancer biomarker detection capability is improved, but analytical sensitivity is insufficient to detect low allele frequency variants in high background wild-type DNA
Solution Approach 1:
The assay segments the detection process into multiple independent steps: (1) target enrichment using hybridization capture with biotinylated probes specific to known cancer variants, (2) unique molecular identifier (UMI) assignment to individual DNA molecules before amplification, (3) variant calling with error correction by comparing UMI sequences. This segmentation allows each step to be optimized independently, achieving detection of variants at allele frequencies below 0.1% by separating true mutant signals from background noise through the UMI-based error correction mechanism.
Solution Approach 2:
Unique molecular identifiers (UMIs) serve as intermediary tags that are ligated to individual cfDNA molecules before amplification. These random nucleotide sequences act as mediators that allow traceability of original template molecules through PCR amplification, enabling the system to distinguish between true mutant alleles and artifacts generated during amplification. The UMI intermediary enables error correction by comparing sequences from multiple amplifications of the same original molecule.
2Measurement precision
If ctDNA detection sensitivity is increased to detect MRD, then early diagnosis capability is improved, but the limit of detection is compounded by small amount of cfDNA from typical blood draw
Solution Approach 1:
The assay performs preliminary target enrichment using hybridization capture before whole-genome or targeted sequencing. Biotinylated RNA or DNA probes complementary to known cancer variant sequences are used to capture and enrich mutant cfDNA fragments from the limited input material. This preliminary enrichment step concentrates the rare mutant molecules while depleting abundant wild-type DNA, enabling effective use of small blood volumes (e.g., 5-10 mL) to achieve detection limits below 0.1% allele frequency.
Solution Approach 2:
The method combines multiple techniques into an integrated workflow: hybridization capture enrichment, UMI-based error correction, and statistical modeling of background error rates. By merging these approaches, the assay achieves ultra-sensitive detection despite limited cfDNA input, as the combined methods multiply their advantages while compensating for individual limitations.
3Ease of operation
If plasma genotyping assays are used for cancer patient management, then noninvasive monitoring capability is improved, but assay accuracy is insufficient for reliable MRD detection
Solution Approach 1:
The assay incorporates statistical feedback mechanisms where background error rates are empirically determined from control samples and used to set dynamic thresholds for variant calling. The system continuously refines its detection criteria based on observed error patterns, adjusting significance thresholds and minimum allele frequency cutoffs to maintain high specificity. This feedback loop ensures that the noninvasive assay achieves clinical-grade accuracy by adapting to actual performance characteristics rather than relying on fixed parameters.
Data Source
AI summary
Techniques for cancer patient management, and more particularly, to techniques for ultrasensitive detection of circulating nucleic acid with prior knowledge of variants to be monitored in the blood. An exemplary technique includes detecting one or more variants in a sample of cell free DNA from a subject. The one or more variants are selected from a plurality of variants known to be specific to a tumor or disease area of the subject. The technique further includes counting the detected one or more variants, determining a tumor burden based on the count of the one or more variants, and determining a statistical significance of the tumor burden based on whether the detection of the one or more variants is associate with true signals or background noise.